FDA Notice to Pharmaceutical Firm for Using Imported Sweeteners

After the seizure of chemicals worth Rs 42 lakh from a chemical company in Bhiwandi last week, the Food and Drugs Administration (FDA) of Maharashtra has now sent a notice to a major pharmaceutical company for using imported food sweeteners in medicines without license.
According to information from the FDA, the pharma company, located in Bhiwandi was illegally selling ‘Lactitol Monohydrate’ chemical from China to many pharmaceutical companies. “After receiving a tip off about illegal imports, raid was conducted at the premises of the Bhiwandi company and found that it was importing the chemical as an ingredient for food products, but selling it to pharmaceutical companies for use in medicines,” said official.
A senior official of FDA said that selling the chemicals without license is illegal under provisions of the Drugs and Cosmetics Act 1940. “During the raid 12,730 kg of Lactitol Monohydrate worth Rs 42 lakh was seized,” added official.
Dr. Harshdeep Kamble, FDA commissioner said that the company had also given an undertaking to the Central Drugs Standard Control Organization (CDSCO) saying that the material would not be used or sold for medicinal purposes.
"During the investigation it was revealed that the company had given an undertaking to the Central government saying that they would import the drugs but not for medicinal use. But the company imported the chemical from a Chinese company and sold it to different pharmaceutical companies so that it will be used in medicines," added Dr. Kamble.
Dr. Kamble further stated that the notices has been issued to the pharmaceutical companies and asked them to give the complete details about the products. “The samples which have been seized are sent to the laboratories for analysis,” added Dr.Kamble.
2026-10-24
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
China’s 15th Five-Year Plan Sets New Priorities for Pharmaceutical Innovation and Supply Chains
-
Evonik Expands Slovakian Fermas Site with €80 Million Investment to Boost Pharmaceutical CDMO Capacity
-
First New UV Filter in Nearly 27 Years: BASF's Tinosorb® S Approved by FDA, Marking a Historic Shift for the U.S. Sunscreen Market
-
India's PV Community Comes Together at the 6th Edition Drug Safety Symposium 2026 – India Chapter to Shape the Future of Patient Safety
-
China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot
-
FDA approves bemotrizinol, a long-used UV filter, for U.S. sunscreens
-
FDA delays proposal to ban formaldehyde in hair straighteners
-
Can Florida's Authorization to Import Prescription Drugs from Canada Lower Medication Prices?
-
FDA Releases New Resources for Food Traceability Final Rule Compliance
-
IFSAC Unveils 2021 Report: Diverse Food Sources Linked to Salmonellosis Cases
Recommend Reading
-
FDA Color Policy Uncertainty Opens a New Chapter for Food Ingredient Reform
-
U.S. Delays Mandatory GRAS Notification Proposal, Pushing Food-Additive Overhaul to Year-End
-
3M, DuPont and Honeywell Must Face Firefighters’ PFAS Turnout-Gear Lawsuit
-
关于加强防范钓鱼邮件的通知 Notification on Strengthening Anti-Phishing Measures
-
U.S. Section 232 Pharmaceutical Tariffs Take Effect, With 100% Base Rate on Patented Drugs and APIs
-
Business Society September 29, 2026 Methanol Trend Analysis: Clear Uptrend
-
Cost Support Weakens + Sluggish Demand, Melamine Continues to Decline
-
Cost Values and Demand-Side Game: PP Prices Consolidate After Rising in July
-
Business Society September 29, 2026 Diesel Trend Analysis: Clear Rise
-
Cost Advantages Support, Polyester Staple Fiber Prices Remain on an Upward Trend